Imunon, Inc. announced the retirement of interim Chief Financial Officer Jeffrey Church, effective July 1, 2026, and the appointment of Josh Blacher to serve as the new interim Chief Financial Officer under a master services agreement with Danforth Health, Inc. Mr. Church will continue in a consulting role with a $10,000 monthly retainer. Imunon, Inc. is a life sciences company focused on developing therapeutic solutions.
